Full Protocol (members only)   Consent Form   HIPAA   Spanish Consent Form

CALGB 9862 - "Molecular Genetic Features of Acute Lymphoblastic Leukemia"

Treatment Plan    (Supplied Drug:  N/A)

Objectives
1)  Use PCR analysis to identify pts w/p190 and p210 BCR-ABL positive ALL and evaluate the clinical significance of these fusion transcripts mesured at time of dx.
2)  Evaluate clinical significance of MRD as defined by BCR-ABL fusion transcripts in pts who have achieved a CR using both qualitative RT-PCR and quantitative (real time) PCR in sequential samples of both blood and bone marrow.
3)  Compare blood w/BM samples for detection and quantification of BCR-ABL transcripts in dx and sequential remission samples.
4)  Pilot PCR detection and quantitation of WT-1 expression at dx, remission, and relapse in BCR-ABL positive and negative ALL and determine the impact of this marker on clinical outcome.

Required Samples
20cc peripheral blood in heparinized (green-top) tubes and 5ml BM aspirate in heparinized (green-top) tubes:

• Prior to initiation of tx (submit 2 green-top tubes each w/5ml of BM aspirate at this time point)
• After Course I
• After Course III
• After Course VI
• Q 6 mos during Maintenance Therapy
• 1 yr following completion of all therapy
• At relapse

Eligibility

• Must have ALL and be entered onto CALGB 19802 or its successor studies. Entry on CALGB 8461 is strongly encouraged.
• Signed informed consent.